GeoVax Labs, Inc. is set to raise around $3.2 million in gross proceeds through a public offering.
The offering comprises approximately 13.2 million units, each containing one share of the company's common stock and warrants to purchase shares at $0.245 per unit.
Roth Capital Partners is the exclusive placement agent for the offering, with an expected closing date around December 22, 2025.
Offering Details
Approximately 13.2 million units to be sold at $0.245 per unit, including warrants to purchase up to 26.5 million shares at the same price.
Gross Proceeds
Expected gross proceeds from the offering are approximately $3.2 million, before deduction of fees and expenses.
Use of Funds
The net proceeds will be utilized for working capital and general corporate purposes.
- The public offering is a significant step in raising funds for GeoVax Labs, Inc.'s ongoing operations and development initiatives.
- The involvement of institutional and individual investors in the offering reflects confidence in the company's clinical-stage biotechnology projects.
- The issuance of warrants alongside the common stock provides potential for additional capital influx in the future.
With the expected $3.2 million proceeds, GeoVax Labs, Inc. is poised to strengthen its financial position and support its biotechnology research and development efforts.